Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous: atoltivimab/maftivimab/odesivimab: 16.67 mg/16.67 mg/16.67 mg per mL in a single dose vial: 33.33 mg/33.33 mg/33.33 mg per mL in a single-dose vial) |
| Drug Class | Zaire ebolavirus glycoprotein directed human monoclonal antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.
Summary
- Atoltivimab, maftivimab, and odesivimab-ebgn (Inmazeb) is used for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients.
- A systematic review/meta-analysis was conducted on Inmazeb's efficacy and safety among Ebola virus disease (EVD) patients; one document was reviewed in this process.
- The study found that when administered at a 3 ml/kg IV dose, Inmazeb reduced the mortality rate by 17% in subjects with EVD.
- Compared to other drugs such as ZMapp Plus or Ebanga used for treating EVD, Inmazeb emerged as the preferred choice due to its superior effectiveness.
- Adverse effects observed during the use of Inmazeb included fever, tachycardia, diarrhoea, vomiting, hypotension, tachypnea, and chills.
- For patients with cardiovascular complications,Ebanga may be considered over Inamzeb but overall supportive care remains essential alongside medication administration to control mortality rates effectively.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Prescribing Information. | 2022 | Regeneron Pharmaceuticals, Inc., Tarrytown, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. | 2022 | Journal of Infection and Public Health |